E. Brendel

发表

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Dirk Strumberg, Dimitris Voliotis, D. Strumberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry.

E. Brendel, C. Siethoff, M. Orth, 2004, Journal of mass spectrometry : JMS.

Determination of nifedipine in human plasma by flow-injection tandem mass spectrometry.

E. Brendel, J. Dankers, J. van den Elshout, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Phase I Trial of Sorafenib in Combination With 5‐Fluorouracil/Leucovorin in Advanced Solid Tumors

A. Figer, E. Brendel, R. Geva, 2012, Journal of clinical pharmacology.

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

M. Piccart-Gebhart, M. Radtke, C. Lathia, 2012, European journal of cancer.

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial

C. Lathia, E. Brendel, A. Awada, 2011, Journal of clinical pharmacology.

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

J. Soria, C. Robert, J. Armand, 2010, Cancer Chemotherapy and Pharmacology.

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

D. Strumberg, R. Hilger, H. Richly, 2009, European journal of cancer.

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.

D. Strumberg, S. Seeber, R. Hilger, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic Profile of Nifedipine GITS in Hypertensive Patients with Chronic Renal Impairment

E. Brendel, R. Kobelt, A. Iaina, 2012, Drugs.

Clinical Pharmacology of Glucosidase Inhibitors

E. Brendel, W. Wingender, 1996 .

Pharmacokinetic interactions of nifedipine and quinidine.

H. Sigusch, E. Brendel, M. Hippius, 1995, Die Pharmazie.

Carvedilol increases the systemic bioavailability of oral digoxin.

E. Brendel, C. D. De Mey, D. Enterling, 1990, British journal of clinical pharmacology.

Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.

E. Brendel, W. Steinke, H. Ahr, 1997, Arzneimittel-Forschung.

Sensitive high-performance liquid chromatographic determination of pseudoephedrine in plasma and urine.

E. Brendel, I. Meineke, C. D. De Mey, 1988, Journal of chromatography.

Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

B. Schwartz, E. Brendel, K. Mross, 2005 .

A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors

M. Piccart-Gebhart, E. Brendel, C. Haase, 2004 .

381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors

M. Piccart, B. Schwartz, E. Brendel, 2004 .

Postprandial changes in supine and erect heart rate, systemic blood pressure and plasma noradrenaline and renin activity in normal subjects

E. Brendel, I. Meineke, C. Mey, 2004, European Journal of Clinical Pharmacology.

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.

D. Strumberg, R. Hilger, B. Schwartz, 2004, International journal of clinical pharmacology and therapeutics.

Routine measurement of plasma catecholamines in clinical pharmacology by high-performance liquid chromatography with electrochemical detection.

E. Brendel, I. Meineke, C. D. De Mey, 1989, Journal of chromatography.

Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.

E. Brendel, B. Schug, F. Donath, 2010, International journal of clinical pharmacology and therapeutics.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

J. Schellens, E. Voest, H. Verheul, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

J. Schellens, E. Voest, H. Verheul, 2010, Clinical Cancer Research.

High-performance liquid chromatographic determination of cefonicid in human plasma and urine.

E. Brendel, I. Meineke, M. Zschunke, 1985, Journal of chromatography.

Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy.

E. Brendel, M. Michel, B. Kremens, 1999, British journal of clinical pharmacology.

E. Brendel, M. Wargenau, B. Schug, 2002, European Journal of Clinical Pharmacology.

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study

E. Brendel, O. Gallego, J. Broto, 2014, Investigational New Drugs.

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

J. Soria, C. Robert, J. Armand, 2007, Clinical Cancer Research.

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

C. Unger, M. Radtke, E. Brendel, 2007, European journal of cancer.

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

M. Piccart, D. Strumberg, B. Schwartz, 2005, British Journal of Cancer.

Assay of antipyrine and its main metabolites 3-hydroxymethylantipyrine, norantipyrine and 4-hydroxyantipyrine in urine.

E. Brendel, I. Meineke, C. D. De Mey, 1989, Journal of pharmaceutical and biomedical analysis.

Stability of 5-aminosalicylic acid and 5-acetylaminosalicylic acid in plasma.

E. Brendel, I. Meineke, E. Stüwe, 1988, Journal of chromatography.

Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine

U. Fuhr, A. Staib, E. Brendel, 1996, European Journal of Clinical Pharmacology.

Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography.

E. Brendel, I. Meineke, M. Zschunke, 1987, Journal of chromatography.

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.

D. Strumberg, S. Seeber, R. Hilger, 2005, Clinical colorectal cancer.

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

D. Strumberg, E. Brendel, C. Xia, 2012, Cancer Chemotherapy and Pharmacology.

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.

S Seeber, C. Unger, D. Strumberg, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Workshop/conference report on EMA draft guideline on validation of bioanalytical methods.

Margarete Brudny-Klöppel, Berthold Lausecker, Henning Blume, 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.

R. Schall, E. Brendel, B. Schug, 2002, British journal of clinical pharmacology.

osmotic drug delivery system.

E. Brendel, M. Eisele, C. Weisemann, 1998 .

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

B. Schwartz, E. Brendel, D. Voliotis, 2003, International journal of clinical pharmacology and therapeutics.

Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union.

E. Brendel, M. Wargenau, B. Schug, 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.

E. Brendel, G. De Nucci, B. Schug, 2008, Clinical Therapeutics.

Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.

E. Brendel, P. V. van Zwieten, B. Schug, 2006, International journal of clinical pharmacology and therapeutics.

Investigation of bioequivalence of a new fixed‐dose combination of acarbose and metformin with the corresponding loose combination as well as the drug–drug interaction potential between both drugs in healthy adult male subjects

E. Brendel, Y. Liu, I. Jang, 2014, Journal of clinical pharmacy and therapeutics.

Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment .

E. Brendel, M. Boettcher, A. Halabi, 2017, International journal of clinical pharmacology and therapeutics.

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

J. Schellens, E. Voest, H. Verheul, 2010, Clinical Cancer Research.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

J. Schellens, E. Voest, H. Verheul, 2008 .

Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63–9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties

E. Brendel, C. Haase, G. Wensing, 2007, European Journal of Clinical Pharmacology.

Pharmacokinetic results of a phase I trial of sorafenib (S) in combination with dacarbazine (DTIC) in patients with advanced metastatic melanoma or other solid tumors

C. Robert, J. Armand, C. Lathia, 2007 .